- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775706
Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects
January 18, 2024 updated by: Hanmi Pharmaceutical Company Limited
A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with SBS-associated intestinal failure (SBS-IF).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study consists of a screening period, a run-in period, a 6-months core treatment period, a 7-months extension treatment period and a 1-month safety follow-up period.
Study Type
Interventional
Enrollment (Estimated)
18
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wooyoung Hong
- Phone Number: +82 2 410 9238
- Email: wooyoung.hong@hanmi.co.kr
Study Locations
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- Recruiting
- UZ Leuven
-
Contact:
- Tim Vanuytsel
-
Principal Investigator:
- Tim Vanuytsel
-
-
-
-
Region Hovedstaden
-
Copenhagen, Region Hovedstaden, Denmark, 2100
- Not yet recruiting
- Copenhagen University Hospital
-
Principal Investigator:
- Palle Bekker Jeppesen
-
-
Region Nordjylland
-
Aalborg, Region Nordjylland, Denmark, 9000
- Not yet recruiting
- Aalborg Universitetshospital
-
Principal Investigator:
- Lars Vinter-Jensen
-
-
-
-
-
Bordeaux, France, 33000
- Recruiting
- Centre hospitalier Universitaire de Bordeaux
-
Principal Investigator:
- Florian Poullenot
-
Clichy, France, 92110
- Recruiting
- Hôpital Beaujon
-
Principal Investigator:
- Joly-Gomez Francisca
-
Lyon, France, 69002
- Not yet recruiting
- Les Hospices Civils de Lyon
-
Principal Investigator:
- Charlotte Bergoin
-
Nice, France, 06300
- Not yet recruiting
- Centre Hospitalier Universitaire de Nice
-
Principal Investigator:
- Stephane Schneider
-
-
-
-
-
Hamburg, Germany, 20099
- Recruiting
- Asklepios Klinik St. Georg
-
Principal Investigator:
- Maasberg Sebastian
-
Tübingen, Germany, 72076
- Recruiting
- Universitätsklinikum Tübingen
-
Principal Investigator:
- Fusco Stefano
-
-
-
-
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Principal Investigator:
- Sanghoon Lee
-
-
-
-
-
Oświęcim, Poland, 32-600
- Recruiting
- Medicome Sp. z o.o.
-
Principal Investigator:
- Mroziak Beata
-
-
Poznan
-
Poznań, Poznan, Poland, 60-355
- Recruiting
- Uniwersytecki Szpital Kliniczny
-
Principal Investigator:
- Matysiak Konrad
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Not yet recruiting
- University of Illinois Hospital & Health Sciences System (UI Health)
-
Principal Investigator:
- Robert E Carroll
-
-
New York
-
New York, New York, United States, 10029
- Not yet recruiting
- Mount Sinai School of Medicine
-
Principal Investigator:
- Iyer Kishore
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Not yet recruiting
- The Cleveland Clinic Foundation
-
Principal Investigator:
- Donald Kirby
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men or women, aged 18 years of age or older with SBS resulting in intestinal failure at the time of signing the informed consent form (ICF) (or country's legal age of majority if the legal age is <18 years)
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- Diagnosis of SBS with the latest intestinal resection being at least 6 months prior to Screening and considered stable regarding the PN/IV need. No restorative surgery planned in the study period.
Exclusion Criteria:
- Any history of colon cancer.
- History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free for at least 5 years
- History of alcohol or drug abuse (within 1 year of screening)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active
|
Randomized, double-blind, placebo-controlled
|
Placebo Comparator: Matching Placebo
|
Randomized, double-blind, placebo-controlled
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs)
Time Frame: for 24 weeks
|
after multiple subcutaneous (SC) doses
|
for 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2022
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
February 25, 2021
First Submitted That Met QC Criteria
February 26, 2021
First Posted (Actual)
March 1, 2021
Study Record Updates
Last Update Posted (Actual)
January 22, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM-GLP2-201
- DOLPHINS-2 (Other Identifier: Hanmi Pharm. Co., Ltd.)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short GutUnited States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaEnrolling by invitationShort Gut SyndromeUnited States
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
Clinical Trials on HM15912 Active
-
Hanmi Pharmaceutical Company LimitedCompletedRenal ImpairmentUnited States
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Unilever R&DCompleted
-
Novozymes A/SAnalyze & RealizeNot yet recruiting
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
University of California, Los AngelesRecruiting
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH); United States...CompletedChronic Low Back Pain | Chronic Neck PainUnited States
-
Chang Gung Memorial HospitalEnrolling by invitationSuspected Non-Alzheimer Disease Pathophysiology (SNAP)Taiwan
-
Lund UniversityVinnova; Antidiabetic Food Centre AFCCompleted
-
University Health Network, TorontoPatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Applied... and other collaboratorsActive, not recruitingDysphagiaUnited States, Canada